News from boehringer ingelheim A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Sep 01, 2015, 10:30 ET

New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients

 Results from an interim analysis of the Phase III RE-VERSE AD™ study demonstrate that 5g of idarucizumab enabled emergency surgery to be...

Aug 27, 2015, 10:30 ET
Eli Lilly and Company logo.

U.S. FDA approves Synjardy® (empagliflozin/metformin hydrochloride) tablets for adults with type 2 diabetes

The U.S. Food and Drug Administration (FDA) has approved Synjardy® (empagliflozin and metformin hydrochloride) tablets, from Boehringer...

Aug 25, 2015, 08:00 ET

FDA and EMA accept regulatory applications for Boehringer Ingelheim's Gilotrif® (afatinib) for treatment of advanced squamous cell carcinoma of the lung

 Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have...

Aug 20, 2015, 07:30 ET
Eli Lilly and Company logo.

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from EMPA-REG OUTCOME®. This is a...

Aug 17, 2015, 13:30 ET
STIOLTO RESPIMAT

New Published Data Show STIOLTO™ RESPIMAT® Provides Clinically Meaningful Improvements in COPD Health-Related Quality of Life Measure

 Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO® 1&2 trials, which show STIOLTO RESPIMAT...

Jul 29, 2015, 08:00 ET

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

 Boehringer Ingelheim announced today that the first U.S. patients have been enrolled in two of the company's international clinical trials,...

Jul 28, 2015, 08:00 ET

Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer

 Boehringer Ingelheim and Hanmi Pharmaceutical Co., Ltd. today announced an exclusive license and collaboration agreement for the development...

Jul 15, 2015, 11:07 ET

Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim welcomes the international evidence-based 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary...

Jun 30, 2015, 08:00 ET
STIOLTO RESPIMAT

STIOLTO™ RESPIMAT® Now Available in the United States for the Treatment of COPD

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray...

Jun 22, 2015, 08:00 ET

Idarucizumab* Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study

Results from an interim analysis of the Phase III RE-VERSE AD™ patient study demonstrate that 5 g of idarucizumab* immediately reversed the...

Jun 16, 2015, 08:30 ET

Phase I Data Published in The Lancet Show Boehringer Ingelheim's Idarucizumab* Reverses Anticoagulant Effects of Dabigatran

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that The Lancet published results from a phase I study investigating the effects of...

May 31, 2015, 09:24 ET

ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung

 Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy...

May 27, 2015, 07:30 ET
Eli Lilly and Company logo.

Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association's 75th Scientific Sessions®

 The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim (BIPI) and Eli Lilly and Company (NYSE:...

May 26, 2015, 08:00 ET
STIOLTO RESPIMAT

FDA Approves Boehringer Ingelheim's STIOLTO RESPIMAT Inhalation Spray as Once-Daily Maintenance Treatment for COPD

Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) approved once-daily STIOLTO™ RESPIMAT® (tiotropium...

May 20, 2015, 11:30 ET

New Data Analyses on Investigational Tiotropium/Olodaterol Respimat Showed Greater Lung Function Improvement Compared to Tiotropium and Olodaterol Alone

Boehringer Ingelheim Pharmaceuticals, Inc. today announced new data analyses from the pivotal Phase III TONADO™ 1&2 studies...

May 18, 2015, 02:00 ET

Boehringer Ingelheim Presents New Data and Analyses Reinforcing the Safety and Efficacy of OFEV® (nintedanib) Capsules

Boehringer Ingelheim announced new data and analyses that provide further evidence to support the efficacy, safety and tolerability of OFEV®...

May 14, 2015, 08:00 ET

Boehringer Ingelheim showcases expanding presence in lung cancer at ASCO with new data including presentation of Gilotrif® (afatinib) overall survival results for squamous cell carcinoma of the lung

 Boehringer Ingelheim today announced that the latest data from its oncology portfolio will be presented at the Annual Meeting of the American...

May 11, 2015, 11:00 ET

Boehringer Ingelheim and Sutter Health Establish Research Collaboration to Improve Patient Care

Boehringer Ingelheim, a family-owned biopharmaceutical company, and Sutter Health, a not-for-profit health system in Northern California, today...

May 05, 2015, 08:00 ET

Boehringer Ingelheim to Present 29 Abstracts at the Annual American Thoracic Society International Conference

 Boehringer Ingelheim Pharmaceuticals, Inc. announced today that 29 abstracts from the company's respiratory portfolio will be presented at the...

Apr 23, 2015, 08:00 ET

FDA Grants Priority Review to Boehringer Ingelheim's Biologics License Application for Idarucizumab*

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the...